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ABSTRACT
The radioimmunoa.ssay of insulin according to the method of
Hales and Randle (56) was the basis of our studies.

In the

method, bovine albumin, (Fraction V powder), was used in all
buffers, in concentrations from 0. 1% to 3. 9%.

Investigators

have reported making effects of insulin activity by bovine and
human albumin preparations, in concentrations from l. ZS% to
5. 5%.

To avoid this, polyvinylpyrrolidone, molecular weight

40, 000, was substituted for albumin in all buffers, with no apparent loss of accuracy.

Since PVP may be kept at room temper-

ature, and la more easily dissolved than albumin, the preparation of the buffers is simplified and the substitution decreases
the cost of the assay.
Problems were al so incurred with the cellulose acetate
membranes used in the assay procedure, due to the non-uniform
retention of free labeled insulin by the membranes.

Gelman

membranes #GA 6, O. 45 U M were found to give the best results, the retention of the free labeled insulin being much lower
and much more uniform.

Wash control samples varied from 14 7

to Z35 CPM (less background) with a standard deviation of 22. 9
for five replicates.

Changes in the scintillation system were also employed, allowing the use of a much less complicated fluor than originally used,
with no apparent loss of accuracy or efficiency.
The final modified assay procedure was used to determine the
activity of "bound" insulin extracts, prepared according to the method
of Antonia.des (25), with and without the presence of sodium tolbutamide.

Sodium tolbutamide has been reported by some investigators

to have extra.pancreatic effects, particularly the release of biologically active insulin from circulating insulin complexes.
In our own work,

''bound" insulin extracts, exhibiting very low

amounts of insulin activity in the absence of sodium tolbutamide,
exhibited significant amounts of insulin activity when incubated for
two hours at 37°C with sodium tolbutamide.

This is a significant

finding, for it strongly substantiates the claim of extra.pancreatic
effects of tolbutamide; it also lends credence to the findings of
Antonia.des concerning "bound" insulin, for his assay methods depended on the biological action of insulin on muscle or adipose tissue.
In these assays, other factors may be acting to mimic the effect of
insulin, and th ere is no guarantee that true insulin is being
measured; but in the radioimmunoassay, the measurement of insulin
activity depends on the structure and conformation of the insulin
molecule, and is not aubject to mimic effects from other !actors.
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CHAPTER I
DIABETES lv1ELLITUS AND ITS W...ETABOLIC EFFECTS

Introduction
The first recorded description of tb.e condition known as diabetes is found in the writings of a Roman, Aretaeus the Cappadocian, around 100 A. D.

He described it as a "melting down of the

flesh and limbs into urine.

11

.From this observation, he attributed

the disease to a malfunction of the kidneys and bladder; hence the
name "diabetes 11 ,

meaning literally ''to pass through 11 •

Since that

time, of course, the art of medicine has progressed immensely,
and our present knowledge of the disease is much more sophisticated,
although far from complete.

The study of diabetes has grown to be

most complex, with many methods avail.able for monitoring and controlling the course of the disease.

The symptomatology of the dis-

ease is itself a very complex one, with many variations in the manifestation of the diabetic state: juvenile-onset, adult-onset, insulindependent, non-insulin-dependent, ketotic, et cetera.

Even more

cornplex is the study of the metabolic changes accompanying the
disease.

All phases of metabolism are affected in some way in the

diabetic state.

Changes in carbohydrate, protein, and lipid metab-

olism all manifest themselves in the course of diabetes.

-1-

,i

Carbohydrate Metabolism
Deficiencies in carbohydrate metabolism are the most
closely allied metabolic abnormalities associated with the diabetic
state.

In fact, the elevated level of blood sugar, which has be-

come the classical indication of diabetes, is due to an impairment
in normal glucose metabolism.

It is here that insulin normally

plays an important role, acting in the first step of the conversion
of glucose into its metabolites, the step resulting in the production
of glucose-6-phospbate.

The action of insulin in this step is con-

sidered to be twofold: (1) It acts directly on the hexokinase system,
increasing the synthesis and availability of the enzyme necessary
for the conversion; (Z) Insulin acts to enhance the production of
glucose-6-phosphate by a transport mechanism in which the insulin
acts as a carrier for transporting the glucose across the cell
membrane, across a concentration gradient.

In the diabetic state,

(that is, one in which the insulin is not present in sufficient quantity, at least, not in the biologically active form), the glucose
I
'

transport system cannot function properly, and the overall metabolism of glucose is impaired.

This in turn causes a build-up of
'I

glucose in the extracellular fluid, and gives rise to the observed
elevation in blood sugar.
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FIGURE I

ABNORMAL CARBOHYDRATE METABOLISM IN
DIABETES MELLITUS
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Lipid Metabolism
Along with the abnormalities in carbohydrate metabolism observed in the diabetic state, there are four major abnormalities in
lipid metabolism associated with the disease.
The first abnormality is the impaired biosynthesis of fatty
acids, first demonstrated by Stetten and Boxer {l), who reported decreased incorporation of deutrium-labeled water into fatty acids in
intact and diabetic rate.

Also, Chaikoff (Z) reported similar findings

using 14-C-labeled glucose, in intact and alloxa.n diabetic rats.
Of course, the very fact that glucose metabolism is disturbed
would account for a concomitant decrease in fatty acid synthesis,
since glucose is a prime source of fatty acids, as shown in Figure II.
However, it has been shown that the deficiency in fatty acid synthesis
is more severe than can be accounted for by this fact alone.

The

synthesis of fatty acids from substances other than glucose, such as
fructose, has been demonstrated to be impaired in the diabetic
state (3).
The second deficiency in lipid metabolism accompanying diabetes is an increased level of fatty acid oxidation.

Lossow and co-

workers (4) have shown direct evidence for an increased rate of oxidation of fatty acids to carbon dioxide in the diabetic •

The direct re -

lationship of this fact to glucose oxidation was also shown, since the

-4-

injection of glucose in normal animals, or the administration of
insulin to diabetics, results in a rapid decrease in fatty acid oxidation.
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FIGURE 11

ABNORMAL LIPID METABOLISM IN DIABETES MELLITUS
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A third abnormal condition in lipid metabolism accompany-

ing diabetes is ketosis.

The development of this condition can be

seen in the following summary, and in Figure III.

The diabetic

must rely on increased fat oxidation for energy, providing acetyl
CoA in sufficient amounts, but resulting in a lack of pyruvate and
NADPH.

Thus, the Kreb's cycle cannot function properly, and

the acetyl CoA is shunted into the production of B-hydroxy-B-methyl
glutaryl CoA, and into the synthesis of ketone bodies (acetone,
acetonacetate, and B-hydroxybutyrate).
Lastly, it bas been found that cholesterol levels are elevated
in the blood of diabetics (5).

There is also much evidence for the

implication of high cholesterol levels in atherosclerosis (6).

Com-

bined with the almost "normal" incidence of atherosclerosis in diabetics, the elevated cholesterol found in diabetic blood is a problem
of utmost concern.
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FIGURE III

PRODUCTION OF KETONE BODIES IN DIABETES MELLITUS
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) (.3-Hydroxybutyrate

PROTEIN METABOLISM

The third major metabolic effect of diabetes is on protein
metabolism.

The lack of insulin and the resulting inability to

metabolize glucose causes a net decrease in protein synthesis,
especially in muscle tissue, with its high demand for a source of
energy.

This decrease is accompanied by an elevated level of

amino acids in the circulation, which in turn are used either to form
glucose, or to form ketone bodies, which are already in excess from
the pathway described in the discussion of lipid metabolism.

DISCUSSION

The effects of the lack of insulin on the body are not limited
to those described above, by any means.

In addition to, and direct-

ly related to, the defects in carbohydrate, lipid, and protein metabolism, the lack of insulin also results in other related maladies,
such as electrolyte imbalance, dehydration, hemoconcentration,
acidosis, peripheral circulatory failure, and many other serious
problems.

The major difficulties observed in and related to dia-

betes, as well as their interrelationships, are listed in Figure IV.
This list is not meant to be comprehensive, but it serves to demonstrate the norm.al course of the disease.
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FIGURE fV

SUMMARY OF METABOLIC AND PHYSIOLOGICAL EFFECTS
OF DIABETES MELLITUS
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CHAPTER II
DIABETES AND BLOOD INSULIN LEVELS

History
The prime factor in diabetes mellitus is, without a doubt,
that of a deficiency in insulin action.

Whether this deficiency is

always due to a lack of insulin production by the pancreas, or some
lack of expression of insulin activity in extrapancreatic tissue, is
not known.

In fact, the development of methods for assaying insulin

levels in the blood has led to many interesting theories on the true
state of the hormone in the circulation, and the relation of the level
of circulating hormone to the level of biologically active material.
Historically, the first idea that linked diabetes to the pancreas
was proposed by Banting in 1929 (7), who suggested that the disease
was due to "a deficiency of the internal secretion of the pancreas,
although we do not know the cause of the deficiency. " At that time,
no relationship between diabetes and blood insulin levels had been
established, due to the fact that only crude methods of determining
insulin concentration were available.
time, this situation did not change.

For quite a long period of
Until the early 1950 1s, not very

much was known about the mode of transport of insulin in the body,
although its physiological properties were fairly well established.
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In 1951, Bornstein and Lawrence (8), working in London,
studied the effects of injections of human serum into hypophysectomized, adrenalectomized rats, rendered diabetic by destruction of
the pancreatic beta cells with allo.xan.
interesting findings.

They reported three very

First of all, they found that serum from nor-

mal fasting humans had the same blood-glucose lowering effect as
50 uU/ml of crystalline insulin

(One unit is defined as the a.mount

of insulin activity contained in O. 0408Z mg of the International Standard Preparation; its physiological definition is the amount of insulin
necessary to reduce the blood glucose level of a normal Z kilogram
rabbit, afte1· a 24-hour fast, from 12.0 to 45 mg/100 ml.
These investigators also found that serum from adult, insulindependent diabetics currently under insulin control had approximately
the same glucose lowering effect as normal serum.

Finally, they

reported that the serum from insulin-dependent juvenile diabetics
had no hypoglycemic effect, and in some cases, made the rate resistant to subsequent injections of crystalline insulin.
While these findings were interesting and theoretically could
be used as the basis of an assay method for insulin activity of serum,
the problems encountered in maintaining adrenalectomized, hypophysectomized rats alive, as well as the problems in reproducibility, made
the method impractical as a standard assay for insulin.
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Rat Diaphragm Muscle Assay
In 1954, Vallance-Owen and Hurlock(9) studied the addition
of insulin to a glucose-containing medium, incubated with isolated
rat diaphragm muscle.

They found that the insulin stimulated glu-

cose uptake and glycogen deposition in the muscle tissue.

They used

this as the basis of the first reliable assay of insulin activity, sensitive to amounts of insulin as low as ZS-50 uU/ml.

Using this assay

method, Vallance-Owen(lO), as well ae other investigators (11). reported that the serum of uncontrolled insulin-dependent diabetics exhibited no insulin activity, while the serum of controlled insulin-dependent diabetics had normal, even excessive amounts of insulinactivity.

This led to the postulation that in some cases of diabetes,

insulin may be present in sufficient quantities to handle a glucose
load in a normal situation, but that some form of antagonist to lnsulin was preventing the eJ4>resaion of the full biological activity of the
hormone.
Rat Epididymal Fat Pad Assay
Another reliable assay of insulin activity was developed by
Renold and coworkers in 1958 (12).

Their assay was based on the

addition of insulin to rat epidldymal fat pad in a suspending medium;
they observed accelerated glucose uptake, increased oxidation of glucoae to carbon dioxide, and increased incorporation of glucose into
glycogen and lipids.

-13-

In general, the values obtained from normal human serum
were higher with the fat pad assay, ranging from values of 33 to
940 uU /ml, with a mean of 290 uU /ml, than were the normal values
reported with the diaphragm muscle assay of Vallance -0\.ven and Hurlock, with a range of 10 to 100 uU/ml, and a mean value of 57 uU/ml
For this reason, the values reported using the fat pad assay were
cautiously designated as insulin-like activity (ILA), to include the
possibility that there may be some other factor besides insulin producing the effects normally attributed to insulin.
Renold and coworkers further reported (13) that the serum of
severe, uncontrolled insulin-dependent diabetics, which bad exhibited
no insulin activity when assayed by the rat diaphragm method, exhibited high levels of ILA with the epididymal fat pad assay.

This in-

troduced the possibility that adipose tissue bad some mechanism for
the utilization of the substance exhibiting ILA, while no such mechanism was acting in muscle tissue.

"Typical" and "Atypical" Insulin
In 1955, Maloney and Coval (14), at the University of Toronto,

produced a specific anti-insulin antibody serum, which abolished the
biological effect of pure crystalline insulin when incubated with rat
adipose tissue or rat diaphragm muscle.

-14-

But the anti-serum, when added to normal human serum, suppressed only a part of the ILA in the fat pad assay, while suppressing all the activity in the diaphragm assay.

In subsequent studies,

Slater and cowoekrrs (15) confirmed these findings and coined the
terms

11

typical 11 and "atypical" insulin, the "typical" form being the

insulin suppressible by insulin anti-serum, and the "atypical" the
form which is not suppressed by the' anti-serum.
Samaan and coworkers (16) were able to separate the two forms
of serum ILA using ultracentrifugation techniques.

They reported

that the "atypical" form bad a molecular weight in excess of 30, 000
and that prolonged acid-ethanol extracti on of the ''atypical" form
caused more than two-thirds of it to be converted to the "typical"
form.
An analysis of the relative amounts of "typical 11 and "atypical 11
#

insulin revealed the following: ''typical" insulin measured in pancreatic venous blood accounted for 90-95% of the total ILA, while in
hepatic venous blood, ''typical 11 insulin represented only about 50%
of the total ILA.

From these findings, Samaan suggested that en-

dogenous insulin, produced in the pancreatic beta cells, was being
altered in some way in the liver, rendering it inactive to insulin
anti-serum, and resulting in the formation of "atypical 11 insulin.
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Froesch and coworkers (17), at the University of Zurich,
used fractional precipitation, gel chromatography, and electrophoresis to isolate and partially purify "atypical" insulin.

They were

able to isolate a substance with non-suppressible ILA when assayed
in either the rat diaphragm or adipose tissue assay method.

It had

an activity of only 2 uU/mg, compared to about 25 uU/mg for pure
crystalline insulin.

However, its properties were very similar to

those of crystalline insulin.
into normal animals.

It induced hypoglycemia when injected

It stimulated glucose uptake, lipid incorpora-

tion of, and carbon dioxide formation from glucose.
lipolysis in the absence of glucose.
G-75 in

5M

It inhibited

When passed through Sephadex

acetic acid, a material was eluted which had a molecular

weight of approximately 6, 000, resembling that of insulin under the
same conditions.

However, when oxidized with performic acid, no

normal insulin A chain was found, using electrophoretic mobility as
the identification method.
This laat fact led Froeach to postulate that some change in
the insulin A chain goes on in the liver, altering its physical
properties so that large aggregates of individual molecules are
formed.

Under the proper conditions, these aggregates may dis-

aociate into units of the same molecular weight and biological
activity as native insulin.

-16-

Keen and coworkers (18, 19) studied extracts of plasma
proteins using trichloroacetic acid precipitation, and TCA-ethanol
extraction procedures.

The fraction collected in this manner was

con1.posed largely of serum albu1nin, and yet h.a.d many insulin-like
properties.

It increased glucose uptake and glycogen deposition by

the isolated rat hemidiaphragm.

It promoted incorporation of labeled

amino acids into muscle protein.

When incubated with fat pad, the

extract accelerated glucose uptake and oxidation. and incorporation
of labeled glucose into lipid.
A large percentage of this activity expressed in the presence

of fat pad was not suppressible by anti-insulin antibody.

This fact

links this fraction very closely with the extracts studied by Froesch.
In 1960, Yalow and Berson (20) developed a very sensitive

assay of insulin based on competition for antibody sites, in potent
anti-insulin serum, between a known quantity of added, labeled insulin and the insulin present in the plasma sample to be assayed.
Estimates of activity using this radioimmunoassay are lower than
those using the bioassays, particularly the fat pad assay.

It is

postulated that only the "typical" (suppressible) insulin-like activity
is being measured in this assay.

The method is reported to be

specific for insulin,. and it is sensitive to amounts of insulin less
than O. 01 uU/ml.
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"Free 1 ' and

11

Bound 11 Insulin

Another very important interpretation of the separation of
serum insulin into more than one component is the theory that the
hormone may exist in the blood partially as free. biologically active
material, along with a biologically inactive form of insulin, bound
to some other plasma constituent&.

Antoniades and coworkers (2.1)

were using acid-ethanol precipitation of plasma in order to isolate
a fraction with ILA.

To prevent coagulation of the blood samples,

one of two methods was employed.

The blood was either treated

with acid citrate dextrose, (ACD), or passed through a cationic exchange resin, to decalcify the samples, and thus inhibit coagulation.
The samples preserved by the treatment with ACD had retained all
of their insulin-like activity, but it was found that the samples
treated with the cationic exchange resin had lost almost all its
activity, measured by the rat diaphragm method. in the presence
of adipose tissue.

This lost activity was regained from the column

by elution with dilute NH 4 OH.
Althoug_.. the eluted substance had no effect on rat diaphragm,
it was found to possess considerable ILA when assayed by the fat
pad assay, or by the diaphragm assay in the presence of adipose
tissue.

If the eluted material was first incubated with saline ex-

tracts of adipose tissue, it regained the ability to stimulate glucose

-18-

uptake by the diaphragm (22).

This regained activity was found by

Shaw and Shuey (23) to be inhibited completely by anti-insulin serum,
indicating that there was true insulin in the resin eluate.
These results, along with the results of other studies in his
own laboratories (24, 25, 26) led Antoniades to postulate that the ILA
retained by the resin was a form of native insulin, complexed with
a basic protein.

He felt that the actual binding of the insulin to

the resim could only be explained by means of this basic protein
complex.

Since insulin itself, at physiological pH, is . negatively

charged, and since human insulin migrated electrophoretically as an
anion, the fact that it is adsorbed onto a cationic exchange resin
indicates that the insulin in the blood may be transported along with
a substance having a higher isoelectric point, most likely a protein.
Antoniades further postulated that the fat pad e4"tract was
somehow able to dissociate the insulin-protein complex, and restore
normal ("typical", suppressible) activity to the insulin (27).
In studies conducted to determine the relative amounts of the

two forms of insulin, which Antoniades termed "free" and "bound 11 ,
in human serum, he reported (28, 29, 30) that an equilibrium existed
between the two for ms of insulin. and that the equilibrium was
shifted toward the "free" form upon ingestion of a glucose load.

In

1
1

the case of some diabetics, it was postulated that one of their main

-19-

problems n1i6ht well be an inability to convert the corn.plexed or
11

bound 11 insulin to the "free 11 form with enough rapidity, or to a

great enough extent, to handle the glucose load, leading to an observed deficiency in total insulin activity,
Electrophoretic techniques were employed to locate the fractions of normal human serum exhibiting ILA, by the bioassay of the
fractions separated on the basis of their mobilities (31).

Some en-

dogenous insulin and all added, labeled insulin was found to migrate
with the albumin fraction and the

0( l

fraction.

This endogenous

insulin is postulated to represent the "free" insulin in plasma, since
pure crystalline insulin, when run separately, migrated to a similar
position.

A second site of substantial ILA was found, again measured

by bioassay, corresponding to the

(3

•globulin region.

insulin was not found to migrate to this position.

Added labeled

Therefore, it was

postulated that this ILA could correspond to the "atypical" or "bound 11
insulin.
Further characterization studies of the insulin-protein complex were undertaken by Antoniades (31).

The resin extracted com•

plex was eluted with dilute ammonium hydroxide, and then either
incubated with rat adipose tissue, or subjected to centrifugation at
pH 9. 8, to try to release the "free" insulin from the complex.

As

had been the case in previous studies. the adipose tissue caused a
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release of IL.A from the cornplcx.
pH 9. 8, the basic protein

It was also found that at

r~-0cipitated,

and the "free" insulin was

detectable in the supernatant after centrifugation.
The effects of dialysis on the complex were also studied (32).
Dialysis of the resin eluate after either weak acid or base elution
had an effect on the ILA.

Undialysed samples exhibited higher

levels of activity than samples dialysed against sodium chloride for
from twelve to twenty-four hours.

This was interpreted by Anton-

iades to indicate that the insulin complexes may recombine slowly
at neutral pH.

Dialysis of the resim eluates at acid pH(Z. 0 to 3.D)

did not free the complex.
Concentrates of the insulin-binding protein were prepared by
subjecting the resin eluates to centrifugation at pH 9. 8.

The col-

lected precipitates were pooled, dissolved in acetate buffer at
pH 4. 0, and subjected to paper electrophoresis in phosphate buffer
at pH 7. 4 for sixteen hours at room temperature.

One substance

only was evident, and it appeared to have a substantial positive
charge, suggesU.na that it was indeed basic in nature.

The protein

did not pass through a cellophane membrane at pH 3. 0 or 7. 0, indicating a relatively large molecular weight.

Its isoelectric point

was considered to be in the region of pH 9. 8, since it was at this
pH that it dissociated from the insulin, and was removed as the
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precipitate upon centrifugation.
Attempts were made to form the insulin complex !!!_. ~
by incubating insulin labeled with iodine-131 with serum samples.
No complexes were found, measured by loss of detectable insulin
activity, after incubation d
twenty-four hours.

s0 c

and

zs 0 c

for from five minutes to

Thia suggested that either there is no large

amount of free insulin-binding protein circulating in the blood, or
that the formation of the complex is of a more complex nature, and
could not be duplicated in a simple incubation.
The dlasociation of the insulin-protein complex upon incubation with adipose tissue extracts in vitro was studied by Antoniades
and Gundersen (27).

Lyophilized resin eluates were dissolved in a

physiological buffer at a concentration of fifteen milligrams of resin
eluate per milliliter of buffer.

One set of samples was assayed by

the rat diaphragm method, without the addition of adipose tissue
extracts.

Identical portions were assayed in the presence of adipose

tissue extracts (O. 5 to l. 0 ml of extract added to 10 ml of incubation
medium).

In all cases, the presence of the adipose tissue extracts

caused a release of the ILA from the resin eluates.

Additional

experiments were performed to determine the effect of varying the
concentration of the adipose tissue extracts on the amount of ILA
released.

It was found that a crude saline extract with a nitrogen
-22-

content of 18 ug/ml of incubating medium was adequate to stimulate
the release of all the available insulin.
This evidence seems to indicate the possibility of an activating mechanism in adipose tissue which enhances the utilization of
the insulin-protein complex, possibly by altering the rate of
dissociation of the complexed form, and thereby increasing the
amount of "free 11 insulin available for utilization.
In vivo studies (33) have indicated that adipose tissue ex-

tracts produce hypoglycemia in insulin-sensitive animals, using
intrave 1ous or intraperitoneal administration of partially purified
adipose tissue extracts, from rat or bovine adipose tissue.

Pre -

liminary studies by Antonia.des on the nature of the active factor
in the extracts indicate that it is heat stable and bas a molecular
eight below 1, 000(34).
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CHAPTER

m

INSULIN ANTAGONISM

According to Vallance -Owen, an insulin antagonist is any
substance or fraction which can modify or combine with insulin
to render it inactive or counteract its effects in vivo or in vitro (35).
Several known substances and some as yet unidentified factors have
been shown to exhibit an antagonistic effect on insulin.

Growth

hormone, epinephrine, and the adrenal cortical steroids are insulin
antagonists, due to their ability to raise blood sugar levels (36, 37).
The antibodies that are commonly used in the radioimmunoassay of
insulin a.re insulin antagonists.

They often appear in the blood of

diabetics who have been under insulin control for an extended period
of time, and they cause insulin resistance in those patients (38).
Non-esteri£ied fatty acids have been implicated as insulin antagonists,
due to their ability to impair glucose uptake in isolated muscle
tissue of the rat (39).

Elevated levels of non-esterified fatty acids

have been shown to be an early marker in the course of diabetes (40).
Vallance-Owen and Hurlock (41) have reported an insulin
antagonist present in preparations of the albumin fractions of plasma
proteins of both normal and diabetic subjects.

At concentrations

of 3, 5 to 5. 5%, both diabetic and normal albumin preparations completely inhibited the effect of 1, 000 uU/ml of insulin in vitro.
-24-

This

range includes the normal physiological concentration of albumin.
At a lower concentration, around I. 25%, only the diabetic albumin
was effective as an antagonist.

After passage through a partially

acetylated cellulose column, the albumin from both normal and diabetic serum had lost all its ability to act as an antagonist, although
it remained electrophoretically identical to albumin.

The name

"synalbumin 11 has been coined in reference to the antagonist,

indicatin~

that the antagonism is apparently due to some other factor associated
with the albumin, and not to the albumin itself.

The antagonistic

effect is not present in albumin preparations from hypophysectomized
subjects, and has been shown to depend on the presence of adrenal
corticosteroids (42).
It bas also been demonstrated that the albumin of pre-diabetics

is antagonistic at 1. 25%, while the albumin of normal subjc :::ts, as
was mentioned earlier, was not antagonistic.

This fact has been

suggested as the basis of a possibly useful diagnostic test for the
early stages of diabetes (43).
The insulin antagonist in albumin preparations has been shown
to have a molecular weight of just under 4, 000.

With this in mind,

and with the fact that in many cases a metabolite of an. active compound may inhibit the action of that compound, the possibility that
the insulin B-chain may be related to the antagonist was considered,

...zs-

for the following reasons.

The B-chain of insulin has a molecular

weight of 3, 800, and is insoluble in phyaiological solutions in the
reduced state.

It bas been found to migrate electrophoretically

with albumin, bound to the albumin, and in this state it is soluble
in physiological solutions (44).
The albumin·B-cbain complex, prepared in vitro using nonantagonistic album.in incubated with small amounts of B-chain, exhibits a high degree of antagonistic activity in the rat diaphragm
assay (45).

If it can be shown definitely that the insulin B-cbain is

identical to the "synalbumin" antagonist, as Vallance-Owen postulates,
then one of the main problems in the diabetic state may be a high
level of circulating B:-ebain, possibly due to an insulin degradation
proceas taking place in the liver or some other extrapancreatic
tissues.
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CHAPTER IV
THE ACTION OF TOLBUTAMIDE

Since insulin is protein in nature, it is subject to attack
from the proteolytic enzymes in the digestive system, resulting
in subsequent lose of biological activity.

For this reason, insulin

must be administered via injection if it is to serve as a beneficial
aid in the treatment of diabetes.

Since the need for the daily in-

jection of insulin causes obvious difficulties for the patient, researchers have long been seeking a subatitute for insulin that could
be administered orally, and thus alleviate much of the danger and
discomfort inherent in insulin therapy.
The first reports of a possible insulin substitute date back
to 1926, when the hypoglycemic effect of the biguanide synthalin
was reported (46).

However, this compound was useless as an

inaulin substitute because of its high degree of toxicity, resulting
in severe liver damage (47).
Many other compounds were studied, moat of them plant
derivatives, but along with the desired hypoglycemic action, they
were all found to be too toxic for use in diabetes therapy.

In 1942(48),

a synthetic compound was reported to have hypoglycemic effects, and
although it was found to be toxic, it paved the way for the development of other synthetic compounds with possible use ae oral hypo-
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glycemic agents.

Since that time, a wide variety of compounds

has been examined, including the tiadiazoles, sulfonylureas, and
guanidine derivatives, the most success having been enjoyed with the
arylsulfonylureas.

Although most of the compounds studied were

found to be too toxic for long-term use, two of them have been subjected to extensive clinical examination, and found to be suitable for
the management of the milder cases of adult diabetes mellitus.
The most widely accepted compound in this class of oral hypoglycemic a.gents is tolbutamide, or more properly, the sodium salt
of tolbutamide.

It was the first sulfonylurea to be marketed in the

United States as a therapeutic agent for the management of diabetes.
The primary action of tolbutamide is the stimulation of the
pancreatic beta cells to secrete insulin (49).

It bas been demon-

strated that patients with mild cases of maturity-onset diabetes do
not have an absolute insulin deficiency; rather, when subjected to a
glucose load, they respond with a very slow rise in plasma insulin
levels, followed by a much delayed peak, and slow decline (50).
Whereas a normal subject will react very quickly to a glucose load
with an immediate release of a small amount of insulin, the diabetic
will respond with much more slowly, with an eventual rise in plasma
insulin levels that equals or exceeds that of the normal subject.
Treatment with tolbuta.mide bas been shown to return the insulin
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response to a glucose load to one more closely resembling the
normal conditions(Sl).

The main interpretation of the mode of action

of this change in response has been that the tolbutamide releases
insulin from the pancreas into the circulation and in this way allows
the patient to respond normally to the glucose load.
Evidence for a dual action of tolbutamide has been presented
by a few investigators.

Antoniades(52) has reported that in addition

to the stimulation of insulin release from the pancreas, tolbutamide
increases the rate of utilization of the inactive form of circulating
insulin in non-diabetic and non-insulin-dependent diabetics.

Intra-

venous administration of tolbutamide in these subjects causes a release of "free" insulin from the pancreas, and a release of "bound"
insulin, either by inhibiting the binding of pancreatic insulin, or by
stimulating the dissociation of the circulating insulin complexes.
Other studies have resulted in similar reports.

Lacy (53)

studied the addition of 100 mg of tolbutamide per ml of normal human
serum, and found that measurable ILA increased from 100 to 120%
over control samples.

Hasselblatt (54) reported that doses of 22 mg

of tolbutamide per 100 ml of serum were sufficient to cause a sig•
nificant release of insulin from serum protein, and at 70 mg per
100 ml, the effect was maximal.
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Gundersen (55) was unable to produce any release of complexed serum insulin with tolbutamide incubation, and restated the
proposition that tolbutamide acts solely on the beta cells of the
pancreas, to increase the secretion of pancreatic insulin, and that
it bas no effect on circulating insulin.
No definitive answer has been agreed upon concerning the
action of tolbutamide, and studies are in progress in several laboratories to attempt to evaluate the conflicting evidence, and to
produce concluaive evidence on the true action or actions of the
drug on insulin release.
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CHAPTER V
:MA.TERIALS AND METHODS
Radioimmunoassay of Insulin
The radioimmunoassay of insulin was carried out according
to a modified form of the method of Hales and Randle (56).
method use$ an antibody specific to insulin.

The

The insulin in the

test solution competes with added radioactive insulin for binding
sites on the antibody.

The resulting insoluble insulin-antibody com-

plex is then filtered out, and measured for radio-activity.

The level

of activity is related in an inverse manner to the amowit of insulin
present in the test solution.

Reagents
1.

Insulin binding reagent-Wellcome Brand, fMR48, batch

llK4908, obtained from Amersham/Searle Corporation, Des Plaines,
Illinois.

The commercial product is prepared in the following

manner.

Anti-sera are prepared to insulin (in guinea pigs) and to

guinea pig serum proteins (in rabbits).

After adjustment of the titer

of an anti-insulin serum, it is diluted in buffer containing EDTA
(ethylenediamine tetraacetic acid) and mixed with a predetermined
amowit of the anti-guinea pig precipitating serum.

The mixture

is allowed to react at 4°C for 18 hours and then freeze-dried.
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When reconstituted to a volume of 8 ml, each vial of the binding reagent contains guinea pig serum precipitate diluted to 1 in

-

16, 000 and 0. 03 M EDTA in Buffer A

(see Table II).

The reconstitution of the powdered reagent was carried
out as follows: to one vial of the powdered reagent, 8 ml of
deionized distilled water was added carefully, and mixed gently
to avoid foaming.

For the assay, volumes of O. 1 ml were dis-

pensed with an Eppendorf micropipette into 10x75 mm disposable
culture tubes (Corning #00445).

Thus, one vial of the reconstituted

insulin binding reagent was sufficient for 80 individual samples.

z.

Insulin standards were prepared according to the procedure

described in Table I.

3.

Aliquots of 0. l ml were used in the assay.

Working Solution of Iodinated Insulin - prepared by adding

0. Z ml of the stock 125-I-inaulin (Amersham/Searle, #IM38,
batch #65, 0. 1 ug in 1. 0 ml of O. 04!'!f_ phosphate buffer, pH 7. 4,
O. 6 m!::f merthiolate, and 0. 5% bovine albumin added) to 7. 8 ml
of Buffer A

(See Table ll).
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Assay Procedure
Volumes of 0. 1 ml of the insulin binding reagent were dispensed into 10x75 mm culture tubes, kept cold in a bench ice bath.
Aliquots of O. 1 ml of the unlabeled insulin standards or the unknowns solutions, or blanks consisting of Buffer B, were added
to the culture tubes containing the binding reagent, and the tubes
were then mixed with a Vortex Jr. Mixer.

The tubes were then

placed in the refrigerator for six hours at 4°C.
After six hours the tubes are removed from the refrigerator
and returned to the bench ice bath.

Aliquots of 0.1 ml of the work-

ing solution of 125-I-lnsulin are added to the tubes, the tubes are
mixed, and then returned to the refrigerator for eighteen hours.
The final composition of a representative set of tubes is given in
Table Ill.
At the end of eighteen hours, the tubes are removed from the
refrigerator and placed in the bench ice bath for processing.

A

microanalysis filtration apparatus is used to collect the precipitated
insulin-antibody complex (Millipore Microanalysis Filter Holder

# XX 10 025 03, with Millipore celluloae acetate membrane filters,
#HAWG 025 00, O. 45 uM, Z5 mm diameter).

The membrane filters

are pre-soaked in cold Buffer C, and applied to the filter holder
using forceps.

The holder is assembled, the line vacuum is applied,
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and the contents of the first tube le drawn up in a diSPo pipette,
5 ... 3/4 11 long.

The contents are carefully applied to the filter ap-

paratus, and the tube is washed twlce with about one ml of cold
Buffer C, the washing• being drawn up into the same pipette, and
applied to the filter.

The filter is then washed twice with one ml

of cold Buffer C, disassembled, and the filter removed with a forceps and scalpel, and transferred immediately to a counting vial.
A new filter is put in place, the apparatus is reassembled, and the
next tube is processed in the same manner.

After all the tubes

have been processed in this manner, they are dried for ten minutes
at l 10°C.

After the tubes have cooled to room temperature, 10 ml

of the ecintillation iluor is pipetted into the vials.
was Fluor I, described in Table IV.

The fiuor used

The samples are then placed

in a Beckman LS-2.50 Liquid Scintillation Counter, allowed to dark
adapt for two hours, and then counted.

In most cases, the samples

were counted for ten minutes, although longer counts were used in
instances where the labeled insulin had lost enough of its activity
through age to warrant a longer count.

The gain control was set

at 360, and the full window isoset was employed, to obtain maximum
efficiency in the counting.

The external standard ratio system of

the instrument was employed to monitor the relative quenching of
the samples. and to determine whether or not corrections for
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quenching would have to be applied to the results.

The external

standard ratio readings reflect the efficiency of the count for each
individual sample; if there is a considerable variation in the external standard ratios of the individual samples, then a correction factor
must be applied to the raw results of the count, to allow for a varying efficiency in counting the different samples.

If the ESR readings,

however, are uniform, then this reflects the fact that the efficiency
of the counts is uniform enough to make any correction factor unnecessary.

It was found that the samples were very much uniform

with respect to the external standard, which meant that no quench
correction would be necessary.
One set of replicates was prepared to obtain a control count.
These tubes were the wash control samples; only iodinated insulin
and buffer were placed in the tubes.

They reflect the degree of

retention of the free labeled insulin by the filter disc.
The results of the count were plotted on semilog paper, with
the net CPM (observed CPM - wash controls) on the logarithmic
scale, and the insulin concentration on the linear scale.

Thus, the

insulin concentration of any unknown samples could be read directly
off the graph.
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TABLE I
PREPARATION OF INSULIN STANDARDS
A.

Preparation of First Stock Solution (ZOO ug/ml)
Two mg insulin (Calbiochem, bovine pancreas insulin,
recrystallized, #40769, lot 53258, B grade, assay ZS uU/mg)
was weighed into a small tube and dissolved in one ml of
O. 03M HCl.

It was transferred to a ten ml volumetric

flask and the tube was washed twice with distilled, deionized
water, the washings being transferred to the flask.
was added to the mark.

Water

This solution was dispensed in

0. 1 ml aliquots into small vials, and stored at

-zo 0 c.

This

solution was found to be stable several weeks after preparation.

B.

Preparation of Second Stock Solution

(2 ug/ml)

Two ml of Buffer B (see table 2) was added to one of the
vials containing 0. l of the first stock solution.

After care•

ful mixing, the solution was transferred to a ten ml volumetric flask, the vial washed twice with Buffer B, the washings transferred to the flask, and the flask filled to the mark
with Buffer B and mixed.

This solution was prepared fresh

for every assay, and kept at 4°C until used.
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C.

Initial Working Standard (ZO ng/ml)
. 05 ml of the Second Stock Solution was placed in a

fifty ml volumetric flask, and diluted to the mark with
Buffer B.

From this solution, a series of standard

solutions was prepared according to the following table.

I
I
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Table I (cont.)

TABLE OF WORKING STANDARDS

STANDARD
NUMBER

*

INITIAL
WORKING
STANDARD (ml)*

FINAL
BUFFER INSULIN
ng/ml
B

CONCENTRATION
uU/ml

1

0.2

9.8

0.4

10

2

0.2

4.8

0.8

zo

3

o.z

1.8

z.o

50

4

1.0

4.0

4.0

100

5

1. 0

1. 5

8.0

200

500 uU/ml or 20 ng/ml
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Table II
BUFFER

SOLUTIONS

-

Buffer A

40 mM phosphate buffer, pH 7. 4 1 for dilution of

antieera and iodinated insulin.

7. 0 gms sodium phosphate monobasic-monohydrate
0. 25 gms domiphen bromide (Mann Laboratories,
No. 6405)

1. 0 gms bovine albumin, Fraction V powder
(Pentex Biochemicals, Lot 98)
Sodium Hydroxide, 2N, to pH 7. 4
Distilled, de-ionized water to 1 liter pH readjusted

to 7.4
Stored at

Buffer B

-

4°c

Buffer for dilution of standard insulin and plasma

samples.

9. 0 gms sodium chloride
Buffer A, to 1 liter
Stored at

Buffer C

4°c

High protein content buffer for washing antibody

precipitates

39 gms bovine albumin, Fraction V powder
Buffer A, to 1 liter
Stored at 4

°c.
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* See

Table I for composition of standards.

**Initial Working Standard
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Table IV
COMPOSITION OF SCINTILLATION FLUORS

Fluor I

-

150 ml ethanol (absolute)
300 ml J?·dioxane (scintillation grade)
50 gms naphthalene (recrystallized from ethanol)
5

gms 2, 5-diphenyloxazole (P. P.O. -Packard, lot #462.7)

Toluene to one liter, stored in a brown bottle, away
from direct light.

Fluor II

-

50 gms naphthalene
5

gms P.P.O.

e_-dioxane, to one liter

Fluor Ill -

5 gms P. P. o.
Toluene to one liter.
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EXTRACTION OF SERUM FRACTION WITH "BOUND INSULIN"
ACTIVITY

A column was packed with Dowex Analytical Grade resin,
AG50-X8, sodium form, (Bio-Rad Laboratories, lot #5369).
resin was first equilibrated with 0. 15

..!:!.

The

NaCl for three hours.

It was then packed in a two cm diameter glass column, to a final
wet volume of 175 ml.

After packing, two liters of 0. lSN -

NazHP04 were passed through the column, making the final pH 6. 6.
100 to 300 ml of pooled human serum (obtained from Veteran's
Administration Research Hospital, 333 E. Huron, Chicago, Ill.)
was passed through the column at a rate of 8 ml/minute.

After

passage of the serum, the column was washed with two resin vols
of 0. 15

~

NaCl, to remove any contaminating substances, followed

by elution of the "bound" insulin fraction with one resin volume of
0. I N

NH4 OH.

The pH of the eluate was monitored with a Radio-

meter pH meter, and kept at 7. O

±. O. 5 with

2!'.:! H 2 so 4 •

After

elution of the "bound" insulin fraction, the eluate was lyophilized at
pH 7.

O,

and stored as the dry powder at

-lo 0 c.

After elution of the ''bound 11 insulin fraction, the column could
be reconstituted by the procedure shown on Table VI.

~--------------4-2-------------~

TABLE V

EXTRACTION OF BOUND INSULIN FROM SERUM

Serum
(100 to 300 ml)

I

Dowex 50W-X8 (Na T Cycle)
175ml Wet Resin Volume

I

0.15M NaCl Wash
(2x Resin Volume)

I

Elution of Bound Insulin

With lrml O.lN NH,oH

2N H2io' to pH 7.0 .:!:: 0.5
Lyoprrization

Stored Frozen As
Dry Powder
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TABLE VI

RECONSTITUTION

OF

RESIN

6 Literi H2 o

3 Lite rs 6M NaCl

H2

I1

to pH 2.7

2 Lite rs 0.2N Na OH

H2

I1

to pH 6.0

1 Liter 0.05r Na 2 HPO. 7H20

3 Liters 0.15M NaCl
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CHAPTER VI
EXPERIMENTAL RESULTS
Experiment I.

First Test of Radioimmunoassar Method for
Measurement of Insulin Activity

The purpose of this experiment was to study the accuracy
and practicality of the radioimmunoassay method as a means for
measuring true insulin activity.
prepared, as per Table I.
10 to 500 uU /ml of insulin.

A set of insulin standards was

They ranged in concentration from
The working solutions of labeled

insulin and insulin binding reagent were prepared as discussed in
Materials and Methods.

The samples were counted for ten minutes,

with Fluor I as the scintillation medium.
in Table Vll.
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The results are listed

Table VII
RESULTS OF EXPERIMENT I

Insulin
Concentration
uU/ml

~;

,,
I

Observed CPM
(Range of 3 Replicates)

Mean CPM

0

2404-3338

2831

10

2069-2610

Z332

20

2074-2397

2198

50

2170-2218

2190

100

2261-2323

2301

200

1886-2195

2006

500

1861-1956

1905

Std. Insulin Blank

328-338

333

Buffer Blank

322-352

335

Wash Control

1139-1726

Fluor Bkg.

75-84

~.··

.,

1462

~\\'
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80

The range of counts for the individual replicates in
Experiment I was so great that no accurate correlation between
observed CPM and insulin concentration could be made.

The

values for different concentrations often overlapped, with the
only reliable readings being those corresponding to the buffer and
insulin blanks and the filter blank.

The range in the wash control

samples (1138.6 to 1726.4) indicated that a problem might be
present in the separation of the free and antibody-bound insulin.
In order to determine whether these results were valid, or
whether the variation was due to some error in the experimental
procedure, it was decided to repeat the experiment, this time
using five replicates instead of three.

Experiment II - Test of Radioimmunoassay Method for Measurement
of Insulin Activity, Five Replicates per Sample
This experiment was essentially a duplication of the first
experiment, with the one exception being the increase from three
to five replicates per sample.
All reagents were prepared fresh.
in Table VIII.
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The results are listed

Table Vill
RESULTS OF EXPERIMENT II

Insulin
Concentration

uU/ml

Observed CPM
Mean of 5 Replicates

Standard
Deviation

0

3111

388

10

2894

*

20

2833

*

50

3029

100

2956

zoo

2595

*
*
*

Wash Control

1051

387

392

27.5

Membrane Blank

*Not Calculated

From calculation of the standard deviation of the control
samples (s. d. =387) and of the tubes with the highest activity,
those containing no unlabeled insulin (s.d. = 388), it was again
found that a great variability exists in the replicates.

With such

a degree of overlap, the assay would be unsuitable for any accurate
determination of insulin concentration, unless a large number of
replicates was run for each sample, to increase the statistical
significance of the results.
Since the variability existed in the wash control samples,
which are really indicative of both the efficacy of the wash procedure and of the retention of free labeled insulin by the membrane
filters, these two factors were considered to be possible sources
of the problem.

After the first experiment, in which the same

variability in the replicates was exhibited, the subsequent wash
procedures were performed very carefully, to avoid any possibility
of non-uniform washing leading to the apparent non-uniform retention of the free labeled insulin.

When this had no efiect, the mem-

brane filters themselves were considered to be the only other
possible source of error.
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Experiment

m ..

Comparison of Two Cellulose Acetate Membrane
Filters With Respect to Retention of Free,
Labeled Insulin

Since the membrane filters were suspected of a lack of
uniformity in retention of free labeled insulin, this experiment
was designed to study the retention properties of the filters used
for the first two experiments, and to study the same properties
of similar filters from another source, to see if a change in
filters could alleviate the difficulty.
Filters Used:
l)

Millipore cellulose acetate membrane filters,
pore size 0.45 um, No. HAWG02500, ZS mm diameter.

Z)

Gelman Metricel cellulose acetate membrane filters,
pore size 0. 45 um, No. GA-6, I-inch diameter.

Suf!icient tubes were set up for five replicates each of Millipore and Gelman filters, with and without the addition of 0. 1 ml of
125-I-insulin.

All filters were soaked in cold Buffer C, then placed

in the filter holder and washed with 5 ml of cold Buffer C.

All

filters were then placed in counting vials, and dried for 10 minutes
at 110°c.

10 ml of Fluor I was then added to each vial, and after

one hour of dark adaptation, they were counted in the usual manner.
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Table IX

RESULTS OF EXPERlMENT III

A)

Gelman filters, no labeled insulin added
CPM

306.1
310.6
361.1

Mean 333. 7

Std. Dev. Z2. 9

355.7

335.l
B)

Millipore Filters, no labeled insulin added
CPM

436.7
395.0

389.0
364.5
376.0
C)

Mean 392. 2

Gelman filters, 9. I ml

Std. Dev. 27. 5

125-I-insulin added

CPM

568.6
481. 2
508.8

Mean 524. 7

Std. Dev. 32. 3

521. 8
543.l
D)

Millipore Filters, O. 1 ml 125-1-insulin added
CPM

1273.8
1586. 4

1572.4
1876.2

Mean 1707.l

2226.9
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Std. Dev. 360.3

The results of Experiment III (depicted graphically in
Figure V) clearly indicated that the variability of replicates
was due to the random retention of iodinated insulin by the
1Hllipore membrane filters, apparently due to a lack of uniformity
of pore size.

The Gelman filters were much more suitable, due

to the much lower retention of labeled insulin, and the uniformity
of the retention, as indicated by the much smaller standard deviation (Millipore 360. 3, Gelman 32. 3).

For this reason, Gelman

filters were used in all subsequent experiments, to assure better
controls.
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E~~periment

IV - Radioimmunoa.ssay of Insulin: Preparation of
Standard Curve Using Fluor II

Once the problem of variability of the replicates had been
solved, another set of standards was prepared, in order to prepa.re a standard curve.

All stock solutions of buffers, insulin

standards, labeled insulin, and insulin binding reagent were prepared fresh.

The working standards were prepared to include

smaller increments than were used previously in order to better
define the standard curve.

As in the previous experiments, five

replicates were prepared for each sample.

The samples were run

as before, using Gelman instead of Millipore filters.

A change

in the scintillation fiuor was introduced, and Fluor ll (see Table
IV) was not used.

Fluor II is a standard scintillation medium,

and was favored over Fluor I because of its relative simplicity and
smaller danger of contamination.

When equal amounts of iodinated

insulin were added to nuor, I and Fluor II, there was no appreciable change in the counting characteristics.
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Table X

WORKING STANDARDS. EXPERThtlENT IV
Initial
Working

Standard ff

Insulin

Standard*

Buffer B

(ml)

(ml)

Cone entration
uU/ml
ng/ml

l

0.2

9.8

10

0.4

2

0.2

4.8

20

0.8

3

o.z

l. 8

50

2.0

4

1. 0

6.5

75

3.0

5

l. 0

4.0

100

4.0

6

2.0

5.5

150

6.0

7

1.0

1.5

200

8.0

8

5.0

500

20.0

* 500 uU/ml. or 20. 0 ng/ml

-ss ..

Table XI
RESULTS OF EXPERIMENT IV
Insulin
Concentration
(uU/ml)

Standard
Deviation

0

3863

Z21

10

15Z4

184

zo

1518

122

50

1136

53

75

855

48

100

635

26

150

600

55

zoo

456

38

500

2.57

48

Wash Control

359 (Obs.)

17

Fluor Bkg.

,~,.

Net CPM (Obs. -wash control)
(Mean of Five Replicates) ,

89
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8

The results of Experiment IV are shown in Table XI.
With the introduction of the Gelman membrane filters into the
assay system, the variability in the retention of free labeled
insulin was alleviated.

This is indicated by the wash control

samples, which remained at a workable level (359 CPM).

This

reading was used as the control level for all samples, and the
observed activity of all other samples was corrected by subtracting
this amount, to account for the retention of free labeled insulin
by the filters.
The standard curve prepared from this experiment is

I

shown in Figure VI.
sc.ale.

I

d

The net CPM is plotted on the logarithmic

From this curve, the concentration of insulin in any

unknown sample can quickly and easily be found, by comparing
the activity of the unknown sample to the standard curve.
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FIGURE VI
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500

Substitution of Polyvinylpyrrollidone for Albumin in Buffer
Solutions

In the portion of this paper dealing with insulin antagonism,
the existence of an insulin antagonist in albumin preparations
was discussed.

To review briefly, Vallance-Owen and Hurlock(41)

have done considerable work in this field, and they report complete antagonism of 1000 uU I ml of insulin, in vitro, by standard
preparations of the albumin fraction of normal and diabetic serum,
in concentrations above 3. 5%.

They further postulate, on the

basis of characterization studie.$ of this "synalbumin 11 insulin
antagonist, that the B- chain of insulin itself may be implicated
as the antagonistic factor in the albumin preparations (42).
Albumin (Fraction V powder) is present in all buffer solutions used in the assay, in concentrations ranging from 0. 1% to
3. 9%.

Because of the above mentioned poesibility of insulin

antagonism of albumin preparations, it was considered prudent
to seek a substitute for albumin, to eliminate the possibility of
interference of the albumin antagonist in the assay, and to assure
that the assay is picking up all the antibody-reactive insulin in
the samples, and that none of it is being rendered unreactive by
the "synalbumin" antagonist.
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In the choice of a substitute for albumin, several factors

had to be considered.

Ideally, the substitute should resemble al-

bumin closely, with respect to molecular weight, solubility, and
solubility-enhancement properties.
pyrrolidone (PVP).

Such a material is polyvinyl-

It is a polymeric substance, whose basic

unit is:

lNAo
I

-CH-CH~
It resembles albumin in its physical properties, but does not have
the same chemical properties associated with albumin.

It is avail-

able in several average molecular weights, 40, 000 being the closest
to that of albumin.

It is used medically as a plasma substitute.

in 3. 5% solution, in cases of hemorrhagic shock.
For these reasons, plus the fact that it can be stored at
room temperature and is much more easily dissolved in water than
is albumin, PVP was chosen as a replacement for bovine albumin
in all buffer solutions used in the assay.

It was used in the same

concentration, and the buffers were prepared and stored under
the same conditions.

In all references to the buffers, the terms
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I

'ii!
11

Al, Bl and Cl will be used to signify the new preparations,

,

I

identical to buffers A , B and C with the one exception being the
change from albumin to PVP.
The new buffers were found to have no detrimental effects
on the accuracy or sensitivity of the assay, (aee Experiment V),
and their use eliminates the danger of interaction of the "synalbumln 11 antagonist with the insulin in the samples.

i

Ii

11,___
____
______.
Ill_
-61-

Experiment V • Release of Bound Insulin by Tolbutamide,
Assayable by Radioimmunoaasay
Bound insulin extracts were prepared from 500 ml of human
serum, the resulting lyophilized resin eluate weighing 1. 347 grams.
A solution of this resin eluate in Buffer Bl, and sodium tolbutamide
in Buffer Bl, and appropriate controls were incubated for two hours
at 37°C.
Table XII.

The composition of the incubation mixtures is shown in
Aliquots from these incubation mixtures were assayed,

along with insulin standards prepared from a standard human
insulin preparation.
XIII.

The insulin standards are described in Table

The buffers used were those prepared with PVP.

The re•

sults of the experiment are shown in Table XIV, and graphically
in Figure VII.
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Table Xll

COMPOSITION OF INCUBATION MIXTURES, EXPERIMENT V

I

Resin Eluate
~z. 78 mg/ml)

Sodium
Tolbutamide*
(0. 037 M)

1-4

1 ml

1 ml

5

1 ml

Tube #

*

Buffer Bl

1 ml

as Sodium Orinaae, Upjohn, Lot #11584-4

-63-

TABLE XIII

PREPARATION OF HUMAN INSULIN STANDARDS, EXPERIMENT V

1.

Standardized human insulin (Amersbam/Searle, Batch 9228,
2. 10 mU). Dissolved in 2 ml of Buffer Bl, made up to
10 ml with additional Buffer Bl.

I
I

I
J

I

This solution contains

210 uU/ml or 8. 4 ng/ml of insulin activity.

2.

Working Standards.
Reconstituted
Std. Insulin
(ml)

Buffer Bl
(ml)

z.o

Final Insulin
Cone entration
uU/ml
ng/ml

210

8.4

2.0

z.o

105

4.2

2.0

6.0

52.5

2. 1

1. 0

9.0

21. 0

0.84

o.s

9.5

10.5

0.42
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Table XIV
RESULTS OF EXPERIMENT

I
I

Insulin
Concentration
(uU/ml)

Observed CPM
(Range of Three
Replicates)

v

Mean Net CPM
(Obs. -Wash Control

210

693-715

374

105

1016-1034

697

52.5

1420-1514

1147

I

Zl.O

1989-2064

1703

l

10.5

2439-2589

2157

2755-2999

2523

I

i

l
I

I

0
Inc.Mix 1

615-647

300

Inc.Mix Z

603-661

299

Inc.Mix 3

637-730

368

Inc.Mix 4

679-746

389

Inc.Mix 5

2615-2887

2404

321-342

0

Wash Control
FlUOl" Bkg.

97-103

99. 9 (obs.)

FIGURE 7
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The results 0£ Experiment V are very significant, in
that although the radioimmunoassay picked up only 2uU /ml of
insulin activity in the sample consisting of bound insulin extract
in Buffer Bl, the samples incubated with the oral hypoglycemic
compound tolbutamide showed a very significant amount of
insulin activity, averaging 244uU/ml of insulin activity for the

four samples.

These activities correspond to actual concentra-

tions of 0. 7 uU of free insulin per mg of the reain extract in

the absence of the oral agent, and 87. 8 uU of free insulin per

mg of the extract in the presence of tolbutamlde.
The activity reported here corresponds well with the
values of 30-100 uU/mg reported by Antontades(Z5), using the

rat diaphragm assay in the presence of adipose tissue extracts.

L
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Summary and Conclusions
I.

I

'''1

The determination of insulin activity by the radioimmunoassay method is a relatively recent development.

It has many

limitations, such as the necessity of access to automated radioactivity counting devices, a tool not available to many laborator-

ies.

Coupled with this is the necessity of maintaining a supply

of lnsulin-I-125, another rather costly factor contributing to the
limited use of the method.

The assay, in the form first used in

our own laboratories, was not sufficiently accurate for an exact
determination of insulin activity, without the use of a minimum

of five replicates for each sample.

The modifications undertaken

in our laboratory have alleviated this somewhat.

In the first place, our experiments have shown that the
choice of the proper membrane filter, among seemingly identical
products, is extremely critical to the precision of the assay.

For

in delivering the assay mixture onto the filtering device, a signifi-

cant amount of free iodinated insulin is retained by the filter.
This amount must be kept both minimal and uniform if the assay

is to be relied upon

Variations in pore size of the filter apparently

contribute to this retention and only filters whose pore characteristics are uniform can be used in the assay.
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For this reason, it

1:

1

111

I

would be prudent to test the pore characteristics of each batch
I,

of filters to be used in the assay, in a manner similar to that
used in Experiment

In.

Secondly, the use of polyvinylpyrrolidone instead of albumin in the buffer solutions is recommended, as a safeguard
against the exhibition of any "synalbumin" insulin antagonism by
the albumin.

This substitution has practical value in addition

to the safeguard described above.

It allows for greater ease of

preparation and handling of the buffers, and reduces the cost of
the assay somewhat.

PVP has been used successfully in our

laboratory as a buffer component, with no discernible adverse
effects on the precision or accuracy of the assay.

It use is one

more assurance that the assay of insulin in this manner is truly
representative of all available chemically intact insulin in the
samples.
The third modification of the assay is centered around
the determination of radioactivity of the samples.

The scintilla-

tion "cocktail" originally used in the assay, and that recommended
for counting samples of this type by Amersham/Searle Radiochem•
ical Center, was found to be unduly complex, and suitable results

were obtained with fluors consisting o! either PPO, naphthalene,
and e,-dioxane, or PPO and toluene.

L

These fluors are more quickly

stabilized, and because of their relative simplicity, they are
advantageous from the standpoint of lower chance of contamination.
The last part of this thesis deals with the adaptation of
the radioimmunoassay of insulin, as modified in our laboratories,
to the determination of the actual insulin content of "bound" insulin
extracts, obtained by ion-exchange separation from human serum.
The fact that the assay showed insignificant amounts of insulin
actlvity in the extracts in the absence of tolbutamide, and quite
significant amounts in the presence of tolbutamide lends credence
to the position taken by Antonia.des, the position that the material
he refers to as ''bound" insulin truly contains chemically intact
insulin.

The major point to remember is that the other assay

methods for insulin depend on its biological activity, and are subject to the presence or absence of many factors, known and unknown,
which may enhance or impair the biological function of insulin.
The radioimmunoassay method depends on the chemical conforma•
tion of the insulin molecule itself and nothing but chemically intact
insulin can bind to an anti-insulin antibody and produce the results
obtained by this method.
The release of the insulin from the "bound 11 form by the
oral hypoglycemic agent, tolbutamide, reported by Antoniades (52),
Lacy (53), and Hasselblatt (54), was observed in our laboratories,

using the radioimmunoa.ssay method.

This release is considered

to be further evidence of the dual role of tolbutamide as a therapeutic agent in diabetes; as described in 1963 by Antoniades (52).
Aside from the stimulation of insulin release from the pancreas
observed with tolbutamide, it may act to increase the rate of
utilization of the inactive or "bound" form of the circulating hormone in insulin-dependent diabetics.
The modifications of the radioimmunoa.ssay method for
determination of insulin, and the dernonstration of true insulin
activity in "bound 11 insulin extracts in the presence of tolbutamide,
lend support for the use of the radioimmunoassay method as a
major tool in the study of two important factors in diabetes
mellitus: first, the role of inactive or ''bound" insulin in the
diabetic state; second, the role of tolbutamide as an important
therapeutic tool in the maintenance of diabetics, and the understanding of the full mechanism of action of the agent ln the maximum utilization of endogenous insulin in the diabetic patient.
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